A detailed history of Bank Of America Corp transactions in Allovir, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 24,118 shares of ALVR stock, worth $13,264. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,118
Previous 22,328 8.02%
Holding current value
$13,264
Previous $16,000 18.75%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.7 - $0.82 $1,253 - $1,467
1,790 Added 8.02%
24,118 $19,000
Q2 2024

Aug 14, 2024

SELL
$0.72 - $0.82 $16,598 - $18,903
-23,053 Reduced 50.8%
22,328 $16,000
Q1 2024

May 15, 2024

SELL
$0.64 - $0.78 $15,859 - $19,329
-24,781 Reduced 35.32%
45,381 $34,000
Q4 2023

Feb 14, 2024

BUY
$0.68 - $2.39 $29,117 - $102,339
42,820 Added 156.61%
70,162 $47,000
Q2 2023

Aug 14, 2023

SELL
$3.17 - $5.82 $1,873 - $3,439
-591 Reduced 2.12%
27,342 $92,000
Q1 2023

May 12, 2023

SELL
$3.94 - $7.05 $8,179 - $14,635
-2,076 Reduced 6.92%
27,933 $110,000
Q4 2022

Feb 10, 2023

BUY
$4.7 - $9.98 $74,913 - $159,071
15,939 Added 113.28%
30,009 $153,000
Q3 2022

Nov 14, 2022

SELL
$4.13 - $8.79 $27,311 - $58,128
-6,613 Reduced 31.97%
14,070 $111,000
Q2 2022

Aug 12, 2022

SELL
$3.26 - $7.06 $8,730 - $18,906
-2,678 Reduced 11.46%
20,683 $80,000
Q1 2022

May 16, 2022

SELL
$6.75 - $13.52 $586,777 - $1.18 Million
-86,930 Reduced 78.82%
23,361 $158,000
Q4 2021

Feb 08, 2022

BUY
$12.94 - $25.99 $1.24 Million - $2.5 Million
96,146 Added 679.72%
110,291 $1.43 Million
Q3 2021

Nov 15, 2021

SELL
$16.97 - $25.06 $39,183 - $57,863
-2,309 Reduced 14.03%
14,145 $355,000
Q2 2021

Sep 13, 2021

BUY
$19.44 - $25.06 $319,865 - $412,337
16,454 New
16,454 $325,000

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $51.2M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.